-
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
•
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United…
-
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…
-
OrbusNeich Files for IPO on Hong Kong Stock Exchange
•
Vascular intervention specialist OrbusNeich Medical Group Limited, a Wholly Owned Foreign Enterprise (WOFE) based in Shenzhen, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE). Details regarding the pricing and timing of the IPO have yet to be released. Company ProfileOrbusNeich is a leading…
